

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Abattis Bioceuticals Corp.
Suite 1040 – 885 West Georgia Street
Vancouver, BC V6C 3E8

Item 2. Date of Material Change

May 1, 2015

Item 3. News Release

A news release dated and disseminated May 1, 2015 at Vancouver, British Columbia, through The Newswire.ca, CSE Markets and SEDAR is attached as Schedule "A".

Item 4. Summary of Material Change

Abattis appoints Hugh Oswald as Investor Relations.

Item 5. Full Description of Material Change

See news release, a copy of which is attached hereto.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Rene David, CFO & COO
Telephone: 604.336.0881

Item 9. Date of Report

May 4, 2015

Schedule "A"

Suite 1040 – 885 West Georgia St.
Vancouver, BC V6C 3E8
Tel: (604) 336.0881
Email: news@abattis.com



ABATTIS APPOINTS HUGH OSWALD AS INVESTOR RELATIONS

Vancouver, BC – May 1, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets – some of which will contain cannabinoid compounds, today announced that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015.

Hugh brings over 15 years of success in the public and private markets conducting Investor Relations and Direct Marketing. Described as a tenacious and enthusiastic professional with an entrepreneurial spirit who is driven, client focused, reliable, dedicated, ethical and trustworthy with expertise in the best communication practices for issuers. He has helped over 15 companies meet their marketing goals.

"I am excited to announce the appointment of Hugh Oswald to reinforce the Company's profile in the investment community and enhance the visibility of our portfolio," stated William (Bill) Fleming, CEO of Abattis. "I look forward to working with Hugh as part of our team at Abattis."

Under the terms of the Agreement, Abattis will issue up to 250,000 shares and share purchase warrants over the next six months. Each full Share Purchase Warrant will be exercisable into one Common Share at the market price after attain certain marketing goals. The expiry date for the exercise of the Warrants will be 5 years from the exercise date. The Warrants will contain an acceleration component whereby Abattis will have the right to call for the exercise of the Warrants if the Common Shares of the Company closes above \$0.25 per share for a period of 10 conservative business days after the four month and one day hold period expires.

The Company further announces the issuance of 371,994 common shares at the \$0.12 of the Company for services rendered during the previous month to Directors, Officers and Consultants and 166,666 Purchase Warrant; which will be exercisable into one Common Share at the market price of \$0.12 per Common Share. The expiry date for the exercise of the Warrants will be 5 years from the exercise date. The Warrants will contain an acceleration component whereby Abattis will have the right to call for the exercise of the Warrants if the Common Shares of the Company closes above \$0.25 per share for a period of 10 conservative business days after the four month and one day hold period expires.

About Abattis Bioceuticals Corp.

For more information, visit the Company's website at: www.abattis.com.

Abattis is a specialty biotechnology company that aggregates, incubates, integrates and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Bill Fleming"

William Fleming, Director & CEO

{00078366;1}

For further information, contact the Company's at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.